Activity Description
In less than 30 minutes, you can watch this on-demand, case-based activity from the proceedings of a CE symposium at the 18th Annual Nurse Practitioners in Women’s Health Conference. Learn about:
- The most up-to-date AHA/ACC/TOS, AACE, ENDO, and ANPF obesity guidelines
- The safety and efficacy of lifestyle strategies for weight-loss
- Collaborating with the patient about implementing lifestyle strategies to maximize weight-loss
Learning Objectives
Upon completion of this activity, learners should be able to:
- Summarize the recommendations for obesity management in practice guidelines from AHA/ACC/TOS, AACE, the Endocrine Society, and ANPF
- Evaluate the efficacy and safety data associated with weight-loss strategies, including lifestyle and dietary interventions and behavioral approaches
- Collaborate with patients to help them identify weight-loss goals and effective weight-loss strategies
Faculty
Mary Annette Hess, PhD, FNP-BC, CNS
Assistant Professor/Family Nurse Practitioner
University of Alabama at Birmingham
School of Nursing
Birmingham, AL
Faculty Biography
Mary Annette Hess, PhD, FNP-BC, CNS
Mary Annette Hess, PhD, FNP-BC, CNS, is an Assistant Professor at the University of Alabama at Birmingham (UAB) School of Nursing and an Affiliate Member of graduate faculty at the University of Alabama in Huntsville. Dr Hess received her BSN degree at Auburn University at Montgomery in Alabama and her MSN degree in Nursing Education at Troy State University in Alabama. She went on to complete her FNP degree and PhD in Health Education and Health Promotion at UAB.
Dr Hess is an active researcher in the prevention and management of prediabetes, diabetes, dyslipidemia, obesity, and diabetes outcomes and is currently a co-investigator for the NIH-sponsored ENCOURAGE-1 and ENCOURAGE-2 (iAdapt) studies. She has authored or co-authored numerous books, book chapters, and journal articles, and presented her research at several national meetings. She is the Chair for the UAB School of Nursing (SON) Faculty Practice committee and a member of the SON Executive Committee. Dr Hess also serves as an educational member for the National Association of Nurse Practitioners in Women’s Health and Gerontological Advanced Practice Nurses Association, and is on the Board of Directors for Southeastern Diabetes Education Services.
Disclosure Statements
NPWH policy requires all faculty to disclose any affiliation or relationship with a commercial interest that may cause a potential, real, or apparent conflict of interest with the content of a CE program. NPWH does not imply that the affiliation or relationship will affect the content of the CE program. Disclosure provides participants with information that may be important to their evaluation of an activity.
Conflicts of interest were resolved according to NPWH policy prior to development of content.
NPWH policy requires authors to disclose to the participant when presenting information about unlabeled use of any commercial product or device or an investigational use of a drug or device not yet approved for any use.
Faculty
Mary Annette Hess, PhD, FNP-BC, CNS
Dr Hess has no disclosures to be made.
She does not discuss information related to any non-FDA-approved or investigational use of any product/device.
Educational Planning Committee
Spire Learning
Erin Franceschini, MS, Lauren Waters, and Lisa Conklin have nothing to disclose.
National Association of Nurse Practitioners in Women’s Health
Susan Rawlins, MS, WHNP-BC, NP, has nothing to disclose.
Disclaimer
The participating faculty determines the editorial content of the CE activity and the content does not necessarily represent the views of NPWH or Spire Learning. This content has been peer reviewed for validation of clinical content. While every effort has been made to ensure that the information is accurate, clinicians are responsible for evaluating this information in relation to generally accepted standards in their own communities and integrating the information in this activity with those of established recommendations of other authorities, national guidelines, FDA-approved package inserts, and individual patient characteristics.
Off-Label Statement
This educational activity does not contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Further, participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Levels of Evidence
Strength of recommendations ratings from the 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults and the Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline are provided for patient care recommendations made during this activity.
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
NHLBI Grading of the Strength of Recommendations |
Grade | Strength of Recommendation |
A | Strong recommendation There is high certainty based on evidence that the net benefit is substantial. |
B | Moderate recommendation There is moderate certainty based on evidence that the net benefit is moderate to substantial, or there is high certainty that the net benefit is moderate. |
C | Weak recommendation There is at least moderate certainty based on evidence that there is a small net benefit. |
D | Recommendation against There is at least moderate certainty based on evidence that there is no net benefit or that risks/harms outweigh benefits. |
E | Expert opinion (“There is insufficient evidence or evidence is unclear or conflicting, but this is what the Work Group recommends.”) |
N | No recommendation for or against (“There is insufficient evidence or evidence is unclear or conflicting.”) |
Source: Jensen MD, et al. Obesity. 2014;22:S1-S410.
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Grade 1: Strong recommendation
Grade 2: Weak recommendation
High quality of evidence (): Consistent evidence from well performed RCTs or exceptionally strong evidence from unbiased observational studies
Moderate quality of evidence (): Evidence from RCTs with important limitations (inconsistent results, methodological flaws, indirect or imprecise evidence), or unusually strong evidence from unbiased observational studies
Low quality of evidence (): Evidence for at least one critical outcome from observational studies, from RCTs with serious flaws, or indirect evidence
Very low quality of evidence (): Evidence for at least one of the critical outcomes from unsystematic clinical observations or very indirect evidence
Source: Apovian CM, et al. J Clin Endocrinol Metab. 2015;100:342-362; Swiglo MH, et al. J Clin Endocrinol Metab. 2008;93:666-673.
Target Audience
This activity is designed for healthcare professionals with an interest in the management of obesity in female patients, including Women’s Health Nurse Practitioners, Adult Nurse Practitioners, Family Nurse Practitioners, and Certified Nurse Midwives.
Accreditation
This activity has been evaluated and approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women’s Health for 0.50 contact hours of continuing education, including 0.50 contact hours of pharmacology content. Each participant should claim only those contact hours actually spent in the educational activity.
Method of Participation
This activity has no fee and should take approximately 30 minutes to complete. Participants should first read the objectives and other introductory CME information, then complete the pre-assessment and participate in the online activity. To receive credit for this activity, participants must complete the post-assessment with a passing score of 70% and then complete the evaluation. This credit is valid through April 14, 2017. No credit will be given after this date. In the event you have questions about this activity or are unable to print the certificate, please e-mail Lauren Waters at lwaters@spirelearning.com, and a certificate will be e-mailed within 2 weeks.
This educational activity is jointly provided by the National Association of Nurse Practitioners in Women’s Health and Spire Learning.
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.